<!DOCTYPE html>
<html>

  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width initial-scale=1" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <title>Accelerating Drug Discovery - The Role of AI in Uncovering New Targets</title>
    <meta name="description" content="A simple, whitespace, helvetica based portfolio theme.
">

    <link rel="stylesheet" href="/css/main.css">
    <link rel="canonical" href="/2024/11/10/AITargetIdentification.html">

    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.7.2/css/all.min.css">
	<link rel="stylesheet" href="/css/academicons.css"/>
    <link href="/css/lightbox.css" rel="stylesheet">

    <link rel="stylesheet" href="/css/zenburn.css"/>

    <!-- collect tags -->
    
      <!-- collect tags from blog posts -->
<!-- source: https://longqian.me/2017/02/09/github-jekyll-tag/ --->







    

	<link type="application/atom+xml" rel="alternate" href="/feed.xml" title="martin-holub.github.io" />
</head>

  
  <!-- Google tag (gtag.js) -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-1ZBQKKLMRB"></script>
  <script>
	window.dataLayer = window.dataLayer || [];
	function gtag(){dataLayer.push(arguments);}
	gtag('js', new Date());

	gtag('config', 'G-1ZBQKKLMRB');
  </script>

  <script type="text/javascript"
    src="http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML">
	</script>

  <body>

    <header class="site-header">

  <div class="wrapper">

    <nav class="site-nav">

      <div class="trigger">
        <!-- martin-holub.github.io instead of blog -->
        <a class="page-link" href="/">about</a>

        <!-- ( for page in site.pages )  was previously-->
        
          
          <a class="page-link" href="/blog">blog</a>
          
        
          
          <a class="page-link" href="/subscribe">subscribe</a>
          
        

      </div>
    </nav>

  </div>

</header>


    <div class="page-content">
      <div class="wrapper">
        <div class="post">

  <header class="post-header">
    <h1 class="post-title">Accelerating Drug Discovery - The Role of AI in Uncovering New Targets</h1>
    <p class="post-meta">November 10, 2024 — 16:22 • <a href="https://martinholub.github.io/2024/11/10/AITargetIdentification.html#disqus_thread">0 Comments</a></p>
    <span class="post-meta">[
      
        
          <a href="/tag/biotech"><code class="highligher-rouge"><nobr>biotech</nobr></code>&nbsp;</a>
      
        
          <a href="/tag/science"><code class="highligher-rouge"><nobr>science</nobr></code>&nbsp;</a>
      
    ]</span>
  </header>
  

  <article class="post-content">
    <p><i>This article was co-authored by <a href="https://www.linkedin.com/in/merchantkevinwb/">Kevin Merchant</a> and <a href="https://www.martinholub.com/">Martin Holub</a>.</i></p>

<h2 id="introduction">Introduction</h2>

<p>Development of novel drugs has been a critical contributor to extending healthspan and fighting diseases, but the process is complex. The involvement of multiple stakeholders and strict regulatory processes are responsible for some of it, but that contribution is dwarfed by our limited understanding of underlying biological processes. Over the past decade, artificial intelligence (AI) has progressed rapidly showing reasoning ability over large multidimensional datasets. AI, indeed, is transforming the drug discovery process as well.</p>

<p>In this article, we highlight the role of AI in a critical task in the early drug discovery process: target identification. We first introduce the technical background. Next, we review the state-of-the-art using industry examples. Finally, we highlight challenges and directions for future development. Questions we address are: <strong>How is AI currently used in target identification?</strong> And: <strong>What future developments of AI would position it to make the largest positive impact on this task?</strong></p>

<h2 id="understanding-target-identification">Understanding Target Identification</h2>

<p>Drug development is a long and complex process, with average estimates of around 12 years from conceptualization to approval — although post-COVID-19, <a href="https://doi.org/10.1016/S0140-6736(22)01276-4">efforts have been made by approval bodies to shorten it</a> [1]. This is happening through a number of approaches, including <a href="https://doi.org/10.1111%2Fcts.12745">accelerated approval pathways</a> [2], leveraging <a href="https://www.statnews.com/2022/08/10/real-world-data-expedite-drug-approval-process/">real world data and evidence</a> as well as <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-efficient-clinical-trial-design-strategies-expedite-development-oncology-drugs-and">changes to clinical trial design</a> [3]. Lead discovery is the first step, including target identification &amp; screening for compounds or biologics against the target, followed by optimization of lead compound and preclinical testing. If the lead compound manages to get through these hoops, it can finally go into clinical trials, where success can pave the way for approval and the title “drug”.</p>

<p>Target identification is an inherent part of academic and industry research. Traditionally, it describes the process of identifying proteins and their roles in specific disease conditions through different experimental methods (Fig.1). A common pipeline is discovering and knocking out the gene coding for the protein of interest and studying the effects on a disease model. Recently, a number of different target types have emerged. Coding and regulatory nucleic acids, both DNA and RNA, different metabolites, and even whole cell types (in the context of cell therapy) all represent potential targets for a drug candidate.</p>

<p>With the arrival of methods like <a href="https://journals.asm.org/doi/full/10.1128/mmbr.67.4.657-685.2003">RNA interference</a> [4] (see also <a href="https://www.martinholub.com/2024/10/16/RNAi.html">my post on RNAi</a>), or more recently <a href="https://royalsocietypublishing.org/doi/full/10.1098/rstb.2015.0496">CRISPR-based tools</a> [5], large-scale screens for experimental target identification have become common in well-resourced labs. Using these methods, a range of genes in disease-model cell lines can be knocked out. Subsequent phenotypic and/or genotypic assaying allows the identification of new possible drug target candidates (Fig.1).</p>

<div class="img_row"> 
<img class="col three" src="/img/techbio_targetIdentification.png" alt="" title="Header" /> 
</div>
<div class="col three caption">Fig.1: Overview of target identification approaches. <a href="https://doi.org/10.1016/j.tips.2023.06.010">Adapted from Pun et al., 2023</a>. </div>

<p>These experimental approaches widen our horizons by characterizing proteins whose functions were not previously known. Most commonly, this knowledge ends up accessible on the internet — through publications — and can be leveraged. Considerable efforts have been made to develop and maintain massive databases containing information on genes, their corresponding proteins, and their function. All of this plays a crucial role in the usage of sequencing technologies, which involve using these databases at some point in their downstream analysis.</p>

<p>In the last decade, with the increased abundance of genomic data, genome-wide association studies (GWAS) have gained a lot of traction. Using GWAS, the genetic makeup of patients suffering from certain ailments can be compared to healthy individuals to identify targets specific to disease pathologies. Similarly, the availability of other omics datasets (transcriptomic, proteomic, epigenomic, metabolomic, etc.) (Fig.1) in the public domain has exponentially increased due to advancements in technologies and lower costs of the corresponding experiments. Consequently, while requiring bioinformatics expertise, leveraging publicly and commercially available multiomics datasets <em>in silico</em> has become a go-to strategy for identifying promising targets before testing them in the lab.</p>

<h2 id="understanding-ai-in-target-identification">Understanding AI in Target Identification</h2>

<p>With the plethora of data and the rapid advances in computer hardware, today there is no domain of biomedical research where AI doesn’t contribute – from information retrieval to clinical diagnoses, and from data processing &amp; integration to protein modeling (<a href="https://alphafold.ebi.ac.uk/about">AlphaFold</a>). AI is an umbrella term that has been used to denote traditional mathematical models such as regression, to abstract phenomena like artificial general intelligence (AGI). The use cases of AI discussed in this article are in between these two extremes. In the following text, we briefly introduce AI as it is being used in target discovery.</p>

<p>Artificial intelligence, or AI, refers to a computer’s ability to perform tasks that are characteristic of intelligent beings. What these algorithms attempt to do is <em>learn</em> trends from swathes of data, and apply what they <em>learned</em> to new, unseen data. For example, an accurate skin cancer detection model has to be fed thousands of images of skin cancer and benign tumors, so that it can <em>learn</em> to discriminate between the two. Similarly, large language models (LLMs) like <a href="https://chat.openai.com/">ChatGPT</a> or <a href="https://www.anthropic.com/claude">Claude</a> are trained on books, articles, and pretty much every text available on the internet in the public domain, which makes them robust in answering a broad range of questions. On the other hand, specialist models like <a href="https://github.com/BioMedBERT/biomedbert">BioMedBERT</a> or <a href="https://www.perplexity.ai/hub/about">Perplexity AI</a>, are geared towards scientific conversations and provide resources and citations.  All these models are examples of deep learning.</p>

<p>Deep learning is a vast subfield of AI that makes use of neural networks. Neurons form the fundamental unit of these networks and are similar to biological neurons: receiving multiple signals from surrounding neurons, processing them in a certain way, and having a single output that is then sent to another neuron. Using multiple layers of such neurons leads to neural networks that come in all <a href="https://www.asimovinstitute.org/neural-network-zoo/">shapes and sizes</a> and varying complexities.</p>

<p>The deep learning models’ ability to learn &amp; generalize makes them extremely versatile in biomedical research. Companies discussed below are using different variations of deep learning to integrate publicly available and self-generated multi-omics datasets along with other types of data like microscopy images, text from biomedical literature, and patient data to capture intricacies and trends that are difficult to detect manually. By training such models biomarkers, perturbation effects, and novel targets can be predicted <em>in silico</em> and subsequently validated through experimentation. Hence, biomedical data in every available form is being leveraged with complex, computation-heavy, and often proprietary AI architectures for identifying new targets against diseases.</p>

<h2 id="case-studies-and-real-world-examples">Case Studies and Real-world Examples</h2>

<p>At the moment of writing, there are <a href="https://doi.org/10.1016/j.tips.2023.06.010">over 20 assets</a> in clinical trials where AI was leveraged for target identification, as well as along the downstream drug development process [6]. A number of them are already in phase II, and many more are in the Investigational New Drug (IND) enabling phase.</p>

<p><a href="https://www.recursion.com/">Recursion Pharmaceuticals</a> is a pioneer in data-driven, platform-first biotech (known as <a href="https://medium.com/cantos-ventures/what-is-techbio-ef01cd61834d">TechBio</a>). Since its founding in 2013, the company built up the capacity to run over 2 million experiments every week and collected over 22 PB (that’s 10<sup>15</sup>) of data. Their pipeline generates lead candidates by applying reverse-genetic causal machine learning models on patient-specific sequencing data and integrating it with health records, databases on small molecule compounds, their target interaction predictions, and data from scientific publications. To facilitate this workflow, the company developed LOWE (Large Language Model-Orchestrated Workflow Engine) that allows users to interface with the pipeline with natural language.</p>

<p>The lead molecules are screened in imaging-based and sc-RNA sequencing workflows, generating genome-wide perturbation datasets that are fed into deep learning models.  Recursion differentiates itself from its competition by being an early and bullish adopter of image-based data collection (phenomics). While <a href="https://www.rxrx.ai/rxrx3#about">a fraction of the generated dataset has been made public</a> [7], much of it remains proprietary to Recursion. Their phenomics foundation model (trained on the publicly available data) <a href="https://www.recursion.com/news/nothing-short-of-phenomenal-new-deep-learning-model-available-on-nvidias-bionemo-platform">Phenome-Beta</a> was released on NVIDIA’s <a href="https://www.nvidia.com/en-us/clara/bionemo/">BioNeMo platform</a> earlier this year. Recursion’s most advanced model, Phenome-1 remains proprietary.</p>

<div class="img_row"> 
<img class="col three" src="/img/techbio_recursionPhenomics.png" alt="" title="Header" /> 
</div>
<div class="col three caption">Fig.2: Overview of ‘phenomics’ for high-throughput screening. Top panel: Cell images are collected at different perturbations (middle) and across multiple color channels (right). Adapted from <a href="https://fintel.io/doc/sec-recursion-pharmaceuticals-inc-1601830-10k-2023-february-27-19415-6506">Recursion’s 2023 annual report</a>. Bottom panel: Multi-channel images are the training data for a deep learning model that learns their experimentally relevant features. The model can be used for future inference. Adapted from <a href="https://www.rxrx.ai/rxrx3">rxrx.ai</a>.</div>

<p>Recursion currently has <a href="https://clinicaltrials.gov/search?spons=Recursion%20Pharmaceuticals%20Inc.">five small molecule drugs in phase II trials</a>. <a href="https://ir.recursion.com/news-releases/news-release-details/recursion-initiates-two-additional-clinical-trials-total-four">REC-4881</a> is an orally bioavailable, non-ATP-competitive allosteric small molecule inhibitor of <a href="https://en.wikipedia.org/wiki/MAP2K1">MAP2K1</a>/<a href="https://en.wikipedia.org/wiki/MAP2K2">2</a> being developed to reduce polyp burden and cancer progression in people living with FAP (familial adenomatous polyposis). FAP is an inherited disease that leads to formation of polyps in the rectum and colon, eventually manifesting in colorectal cancer (CRC). <a href="https://ir.recursion.com/news-releases/news-release-details/recursion-announces-completion-phase-1-study-rec-3964">REC-3964</a> is a non-antibiotic small molecule inhibitor of C.difficile toxins which is being developed for the potential treatment of gastrointestinal infection. It finished phase I in 2023, and started enrollment for phase II in October 2024. Most recently <a href="https://ichgcp.net/clinical-trials-registry/NCT06678659">REC-1245</a> entered phase I/II clinical trials for advanced metastatic tumors</p>

<p><a href="https://insilico.com/">InSilico Medicine</a> is another early adopter of AI in small molecule drug discovery and design. The company leverages its end-to-end integrated Pharma.AI platform consisting of three components to drive its drug discovery and development: <a href="https://pubs.acs.org/doi/full/10.1021/acs.jcim.3c01619">PandaOmics</a>, <a href="https://pubs.acs.org/doi/full/10.1021/acs.jcim.2c01191">Chemistry42</a> and <a href="https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.3008">inClinico</a> [8-10]. PandaOmics is an AI target identification engine that combines a diverse range of omics data totalling over 10<sup>12</sup> data points across disease-specific and healthy tissue datasets. The platform further integrates text-based analysis on clinical trials, grants and publications, all together allowing for identification of novel targets that meet a large need. “Our target discovery philosophy is to find an optimal balance between commercial tractability, novelty, and confidence,” <a href="https://www.drugdiscoverytrends.com/insilico-ai-cancer-treatment-ism9274/?utm_source=TrendMD&amp;utm_medium=cpc&amp;utm_campaign=Drug_Discovery_and_Development__TrendMD_0">said</a> Alex Zhavoronkov, founder and CEO of Insilico Medicine for Drug Discovery &amp; Development.</p>

<p>The company currently has one asset in a phase II trial, <a href="https://clinicaltrials.gov/search?spons=InSilico%20Medicine%20Hong%20Kong%20Limited">four more in phase I</a>, and one preclinical asset. <a href="https://www.nature.com/articles/s41587-024-02143-0">INS018_055</a> is an orally available small molecule TRAF2- and NCK-interacting kinase (TNIK) inhibitor with therapeutic potential in idiopathic pulmonary fibrosis currently in phase II trials [11]. <a href="https://www.businesswire.com/news/home/20230912041846/en/Exelixis-and-Insilico-Medicine-Enter-into-Exclusive-Global-License-Agreement-for-ISM3091-a-Potentially-Best-in-Class-USP1-Inhibitor">ISM3091/XL309</a> is a small molecule inhibitor of USP1, an enzyme implicated in DNA damage repair and relevant in the context of some forms of ovarian, prostate, and breast cancers, <a href="https://www.drugdiscoverytrends.com/insilico-medicines-latest-ai-engineered-drug-ism5411-could-provide-a-novel-approach-for-treating-ibd/">ISM5411</a> is an oral prolyl hydroxylase domain (PHD) inhibitor for the treatment of inflammatory bowel disease (IBD), this investigational drug is supposed to regulate levels of hypoxia-inducible factor 1alpha (HIF-1a), which should in turn control gut inflammation. Finally, the firm has a CDK12/13 inhibitor, <a href="https://www.drugdiscoverytrends.com/insilico-ai-cancer-treatment-ism9274/?utm_source=TrendMD&amp;utm_medium=cpc&amp;utm_campaign=Drug_Discovery_and_Development__TrendMD_0">ISM9274</a>, in the preclinical pipeline that shows promise against multiple cancers, particularly triple-negative breast cancer and pancreatic cancer.</p>

<p>While others focus purely on target-identification (e.g. <a href="https://biorelate.com/company">Biorelate</a>), most companies integrate AI-driven target identification into a full drug development pipeline (further examples include  <a href="https://www.valohealth.com/">Valo Health</a>, <a href="https://relaytx.com/">Relay Therapeutics</a>, <a href="https://www.exscientia.ai/pipeline">Exscientia</a> (recently <a href="https://investors.exscientia.ai/press-releases/press-release-details/2024/Recursion-and-Exscientia-Enter-Definitive-Agreement-to-Create-a-Global-Technology-Enabled-Drug-Discovery-Leader-with-End-to-End-Capabilities/default.aspx">acquired</a> by Recursion), <a href="https://www.nimbustx.com/">Nimbus Therapeutics</a>, and <a href="https://www.benevolent.com/pipeline/">Benevolent A</a>. Finally, <a href="https://www.opentargets.org/">Open Targets</a> stands out as a notable example of open and collaborative science, bringing multiple industry stakeholders together to share disease and target annotation data in easily accessible format.</p>

<h2 id="future-outlook-and-challenges">Future Outlook and Challenges</h2>

<p>When applying AI to target discovery, a number of challenges emerge. First, any model is only as good as the data it has been trained on. Failing to collect data in areas of unmet needs or for underserved patient populations is at large risk of leading to biased models that exacerbate health inequality. Second, AI models have only limited transparency, and to an extent function as black boxes. Managing their regulatory compliance and data integrity requires teams to adapt to changing frameworks. Third, training AI models requires substantial computational resources. This presents challenges to equity of access, where well-resourced companies may benefit from preferential access to compute hardware. Finally, a culture of keeping these models, and the data they have been trained on, proprietary is likely to create silos of knowledge and hinder progress.</p>

<p>Despite these challenges, AI has clearly taken a firm hold across the drug development pipeline, including target identification. The increased volume and modality of datasets, together with more computational power and advances in AI architectures, are increasing the rate at which new candidates are discovered and enter clinical trials. In the future, there is a hope that AI will substantially increase the success rate of these trials as well as be helpful in aiding the development of drugs for previously intractable targets. Examples in this article have focused on protein targets and small-molecule drugs. It is likely that AI-driven models optimized for discovery of different targets than proteins will emerge in the near future. Similarly, other modalities than small molecules are poised to gain more prominence. <a href="https://www.nature.com/articles/s41589-023-01524-x">Peptide-based therapeutics</a> [12], for example, have seen <a href="https://drughunter.com/articles/mk-0616-the-2023-molecule-of-the-year/">a number of successes</a> in the last year.</p>

<p>The future of AI in drug discovery is bright. If you want to learn more about how AI is revolutionizing biotech and stay up to date, be sure to check <a href="https://linktr.ee/aixbiotech_nucleate">Nucleate’s AI in Biotech</a> initiative.</p>

<p><i>We would like to thank Alice Martin, Natalie Losada, Samantha Avina and Shawn Rumrill for feedback on the draft.</i></p>

<hr />

<h2 id="references">References</h2>

<p>[1] Hwang, T. J.; Trinh, Q.-D.; Tibau, A.; Vokinger, K. N. Reforms to Accelerated Approval of New Medicines: Long Overdue. <em>The Lancet</em> <strong>2022</strong>, <em>400</em> (10349), 357–358. <a href="https://doi.org/10.1016/S0140-6736(22)01276-4">https://doi.org/10.1016/S0140-6736(22)01276-4</a>.</p>

<p>[2] Cox, E. M.; Edmund, A. V.; Kratz, E.; Lockwood, S. H.; Shankar, A. Regulatory Affairs 101: Introduction to Expedited Regulatory Pathways. <em>Clinical Translational Sci</em> <strong>2020</strong>, <em>13</em> (3), 451–461. <a href="https://doi.org/10.1111/cts.12745">https://doi.org/10.1111/cts.12745</a>.</p>

<p>[3] Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics. <em>Clinical Trial Design</em>. <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-efficient-clinical-trial-design-strategies-expedite-development-oncology-drugs-and">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-efficient-clinical-trial-design-strategies-expedite-development-oncology-drugs-and</a></p>

<p>[4] Agrawal, N.; Dasaradhi, P. V. N.; Mohmmed, A.; Malhotra, P.; Bhatnagar, R. K.; Mukherjee, S. K. RNA Interference: Biology, Mechanism, and Applications. <em>Microbiol Mol Biol Rev</em> <strong>2003</strong>, <em>67</em> (4), 657–685. <a href="https://doi.org/10.1128/MMBR.67.4.657-685.2003">https://doi.org/10.1128/MMBR.67.4.657-685.2003</a>.</p>

<p>[5] Hille, F.; Charpentier, E. CRISPR-Cas: Biology, Mechanisms and Relevance. <em>Phil. Trans. R. Soc. B</em> <strong>2016</strong>, <em>371</em> (1707), 20150496. <a href="https://doi.org/10.1098/rstb.2015.0496">https://doi.org/10.1098/rstb.2015.0496</a>.</p>

<p>[6] Pun, F. W.; Ozerov, I. V.; Zhavoronkov, A. AI-Powered Therapeutic Target Discovery. <em>Trends in Pharmacological Sciences</em> <strong>2023</strong>, <em>44</em> (9), 561–572. <a href="https://doi.org/10.1016/j.tips.2023.06.010">https://doi.org/10.1016/j.tips.2023.06.010</a>.</p>

<p>[7] Fay, M. M.; Kraus, O.; Victors, M.; Arumugam, L.; Vuggumudi, K.; Urbanik, J.; Hansen, K.; Celik, S.; Cernek, N.; Jagannathan, G.; Christensen, J.; Earnshaw, B. A.; Haque, I. S.; Mabey, B. RxRx3: Phenomics Map of Biology. February 8, 2023. <a href="https://doi.org/10.1101/2023.02.07.527350">https://doi.org/10.1101/2023.02.07.527350</a>.</p>

<p>[8] Kamya, P.; Ozerov, I. V.; Pun, F. W.; Tretina, K.; Fokina, T.; Chen, S.; Naumov, V.; Long, X.; Lin, S.; Korzinkin, M.; Polykovskiy, D.; Aliper, A.; Ren, F.; Zhavoronkov, A. PandaOmics: An AI-Driven Platform for Therapeutic Target and Biomarker Discovery. <em>J. Chem. Inf. Model.</em> <strong>2024</strong>, <em>64</em> (10), 3961–3969. <a href="https://doi.org/10.1021/acs.jcim.3c01619">https://doi.org/10.1021/acs.jcim.3c01619</a>.</p>

<p>[9] Ivanenkov, Y. A.; Polykovskiy, D.; Bezrukov, D.; Zagribelnyy, B.; Aladinskiy, V.; Kamya, P.; Aliper, A.; Ren, F.; Zhavoronkov, A. Chemistry42: An AI-Driven Platform for Molecular Design and Optimization. <em>J. Chem. Inf. Model.</em> <strong>2023</strong>, <em>63</em> (3), 695–701. <a href="https://doi.org/10.1021/acs.jcim.2c01191">https://doi.org/10.1021/acs.jcim.2c01191</a>.</p>

<p>[10] Aliper, A.; Kudrin, R.; Polykovskiy, D.; Kamya, P.; Tutubalina, E.; Chen, S.; Ren, F.; Zhavoronkov, A. Prediction of Clinical Trials Outcomes Based on Target Choice and Clinical Trial Design with Multi‐Modal Artificial Intelligence. <em>Clin Pharma and Therapeutics</em> <strong>2023</strong>, <em>114</em> (5), 972–980. <a href="https://doi.org/10.1002/cpt.3008">https://doi.org/10.1002/cpt.3008</a>.</p>

<p>[11] Ren, F.; Aliper, A.; Chen, J.; Zhao, H.; Rao, S.; Kuppe, C.; Ozerov, I. V.; Zhang, M.; Witte, K.; Kruse, C.; Aladinskiy, V.; Ivanenkov, Y.; Polykovskiy, D.; Fu, Y.; Babin, E.; Qiao, J.; Liang, X.; Mou, Z.; Wang, H.; Pun, F. W.; Ayuso, P. T.; Veviorskiy, A.; Song, D.; Liu, S.; Zhang, B.; Naumov, V.; Ding, X.; Kukharenko, A.; Izumchenko, E.; Zhavoronkov, A. A Small-Molecule TNIK Inhibitor Targets Fibrosis in Preclinical and Clinical Models. <em>Nat Biotechnol</em> <strong>2024</strong>. <a href="https://doi.org/10.1038/s41587-024-02143-0">https://doi.org/10.1038/s41587-024-02143-0</a>.</p>

<p>[12] Pal, S.; ‘T Hart, P. Imbuing Peptide Libraries with Drug-Likeness. <em>Nat Chem Biol</em> <strong>2024</strong>. <a href="https://doi.org/10.1038/s41589-023-01524-x">https://doi.org/10.1038/s41589-023-01524-x</a>.</p>


  </article>

  
<!---
Call Fontawesome in the head section or in the location where you place the share bar
<link href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css" rel="stylesheet">
--->
<hr>
<br/>
<!---<center><p><script async src="https://eocampaign1.com/form/cfe45fdc-109a-11ef-a9e2-bf0899395051.js" data-form="cfe45fdc-109a-11ef-a9e2-bf0899395051"></script></p></center>--->
<div class="share-box center" style="width: 60%; margin: 0px auto;">
<h2 class="center">Share this:</h2>
<br/>
<a class="l" href="https://www.linkedin.com/shareArticle?mini=true&url=/2024/11/10/AITargetIdentification.html&title=Accelerating Drug Discovery - The Role of AI in Uncovering New Targets&summary=&source=martinholub" onclick="window.open(this.href, 'mywin',
'left=20,top=20,width=500,height=500,toolbar=1,resizable=0'); return false;"><i class="fa-brands fa-linkedin"></i><span> linkedin</span></a>

<a class="t" href="https://twitter.com/intent/tweet?text=Accelerating Drug Discovery - The Role of AI in Uncovering New Targets&url=/2024/11/10/AITargetIdentification.html" onclick="window.open(this.href, 'mywin',
'left=20,top=20,width=500,height=500,toolbar=1,resizable=0'); return false;"><i class="fa-brands fa-square-x-twitter"></i><span> x</span></a>

<a class="t" href="https://bsky.app/intent/post?text=Accelerating Drug Discovery - The Role of AI in Uncovering New Targets&url=/2024/11/10/AITargetIdentification.html" onclick="window.open(this.href, 'mywin', 'left=20,top=20,width=500,height=500,toolbar=1,resizable=0'); return false;">
  <i class="fa-brands fa-square-bluesky"></i><span> bluesky</span>
</a>
<!---
<a class="g" href="https://plus.google.com/share?url=/2024/11/10/AITargetIdentification.html" onclick="window.open(this.href, 'mywin',
'left=20,top=20,width=500,height=500,toolbar=1,resizable=0'); return false;" ><i class="fa fa-google-plus fa"></i><span> google</span></a>
--->
<a class="r" href="http://www.reddit.com/submit?url=/2024/11/10/AITargetIdentification.html" onclick="window.open(this.href, 'mywin',
'left=20,top=20,width=900,height=500,toolbar=1,resizable=0'); return false;"><i class="fa-brands fa-square-reddit"></i><span> reddit</span></a>

<a class="f" href="https://www.facebook.com/sharer/sharer.php?u=/2024/11/10/AITargetIdentification.html" onclick="window.open(this.href, 'mywin',
'left=20,top=20,width=500,height=500,toolbar=1,resizable=0'); return false;" ><i class="fa-brands fa-square-facebook"></i><span> facebook</span></a>

<a class="e" href="mailto:?subject=Accelerating Drug Discovery - The Role of AI in Uncovering New Targets&amp;body=Check out this site /2024/11/10/AITargetIdentification.html"><i class="fa fa-envelope fa"></i><span> email</span></a>
</div>
<br/>
<hr>


  

<div id="disqus_thread"></div>
    <script type="text/javascript">
        /* * * CONFIGURATION VARIABLES: EDIT BEFORE PASTING INTO YOUR WEBPAGE * * */
        var disqus_shortname = 'martinholub'; // required: replace example with your forum shortname
        /*var disqus_developer = 1; // Comment out when the site is live */
        var disqus_identifier = "/2024/11/10/AITargetIdentification.html";

        /* * * DON'T EDIT BELOW THIS LINE * * */
        (function() {
            var dsq = document.createElement('script'); dsq.type = 'text/javascript'; dsq.async = true;
            dsq.src = '//' + disqus_shortname + '.disqus.com/embed.js';
            (document.getElementsByTagName('head')[0] || document.getElementsByTagName('body')[0]).appendChild(dsq);
        })();
    </script>
    <noscript>Please enable JavaScript to view the <a href="http://disqus.com/?ref_noscript">comments powered by Disqus.</a></noscript>
    <a href="http://disqus.com" class="dsq-brlink">comments powered by <span class="logo-disqus">Disqus</span></a>




</div>

      </div>
    </div>

<!--
    <span class="contacticon center">
  <a href="https://www.instagram.com/scimartin/" target="_blank"><i class="fa-brands fa-square-instagram"></i></a>
  <a href="https://www.linkedin.com/in/scimartin" target="_blank"><i class="fa-brands fa-linkedin"></i></a>
  <a href="https://bsky.app/profile/scimartin.bsky.social" target="_blank"><i class="fa-brands fa-square-bluesky"></i></a>
  <div class="iconsuperwrapper">
  <a href="https://paragraph.xyz/@scimartin" target="_blank">
  <div class="iconwrapper">
  <svg
   class="icon"
   version="1.0"
   width="36"
   height="36"
   viewBox="0 0 36 36"
   preserveAspectRatio="xMidYMid meet"
   id="svg10"
   sodipodi:docname="paragraph.svg"
   inkscape:version="1.1.1 (3bf5ae0d25, 2021-09-20)"
   xmlns:inkscape="http://www.inkscape.org/namespaces/inkscape"
   xmlns:sodipodi="http://sodipodi.sourceforge.net/DTD/sodipodi-0.dtd"
   xmlns="http://www.w3.org/2000/svg"
   xmlns:svg="http://www.w3.org/2000/svg">
  <path
     id="path4"
     d="M 0 0 L 0 12.7273 L 0 25.4546 L 3.73818 25.4546 C 6.04363 25.4546 7.49818 25.4255 7.52727 25.3819 C 7.54909 25.3455 7.61454 25.331 7.66545 25.3528 C 7.82545 25.411 9.96371 25.4254 9.96371 25.3673 C 9.96371 25.3382 10.0073 25.331 10.0582 25.3528 C 10.1164 25.3746 10.2546 25.3964 10.371 25.4037 C 10.5383 25.4182 10.5819 25.4545 10.5746 25.5854 C 10.5746 25.6727 10.5964 25.7455 10.6255 25.7455 C 10.6546 25.7455 10.6546 25.84 10.6183 25.9564 C 10.5892 26.0655 10.5892 26.2036 10.6183 26.2618 C 10.6547 26.3127 10.6547 26.4073 10.6183 26.4728 C 10.5819 26.5382 10.5819 26.6327 10.6109 26.6764 C 10.64 26.7273 10.6473 26.9309 10.6183 27.1273 C 10.5892 27.3237 10.5964 27.5274 10.6255 27.5783 C 10.6546 27.6219 10.6546 27.7164 10.6183 27.7819 C 10.5819 27.8473 10.5819 27.9419 10.6183 28 C 10.6547 28.0582 10.6547 28.1528 10.6183 28.2182 C 10.5819 28.2837 10.5819 28.3782 10.6183 28.4364 C 10.6474 28.4873 10.6474 28.611 10.6183 28.6983 C 10.5747 28.8001 10.5819 28.8873 10.6183 28.9091 C 10.6547 28.9309 10.6547 29.0401 10.6183 29.1637 C 10.5819 29.2873 10.5819 29.3819 10.6183 29.3819 C 10.6547 29.3819 10.6547 29.4764 10.6183 29.6001 C 10.5819 29.7237 10.5819 29.8183 10.6183 29.8183 C 10.6547 29.8183 10.6547 29.9128 10.6183 30.0364 C 10.5819 30.1528 10.5746 30.2546 10.6037 30.2546 C 10.6328 30.2546 10.6546 30.3709 10.6546 30.5091 C 10.6546 30.6473 10.6328 30.7636 10.6037 30.7636 C 10.5746 30.7636 10.5819 30.8582 10.6183 30.9818 C 10.6547 31.0982 10.6547 31.2 10.6183 31.2 C 10.5892 31.2 10.5819 31.2874 10.6109 31.3965 C 10.64 31.5128 10.6401 31.7164 10.6183 31.8691 C 10.5892 32.0146 10.5892 32.1746 10.6255 32.2255 C 10.6546 32.2764 10.6546 32.371 10.6183 32.4364 C 10.5819 32.5019 10.5819 32.5964 10.6183 32.6546 C 10.6547 32.7128 10.6547 32.8073 10.6183 32.8728 C 10.5819 32.9383 10.5819 33.0328 10.6183 33.091 C 10.6474 33.1419 10.6474 33.2655 10.6183 33.3527 C 10.5747 33.4546 10.5819 33.5419 10.6183 33.5637 C 10.6547 33.5855 10.6547 33.6945 10.6183 33.8182 C 10.5819 33.9418 10.5819 34.0364 10.6183 34.0364 C 10.6547 34.0364 10.6547 34.1309 10.6183 34.2545 C 10.5819 34.3782 10.5819 34.4727 10.6183 34.4727 C 10.6547 34.4727 10.6547 34.5673 10.6183 34.6909 C 10.5819 34.8073 10.5746 34.9091 10.6037 34.9091 C 10.6619 34.9091 10.6546 35.4037 10.5965 35.4619 C 10.5747 35.4837 10.582 35.5782 10.6183 35.6727 C 10.6547 35.7673 10.6619 35.8618 10.6401 35.8837 C 10.611 35.9055 16.3128 35.9273 23.2946 35.9273 L 36 35.9273 L 36 22.5455 L 36 9.16364 L 34.7273 9.16364 L 33.4546 9.16364 L 33.4546 21.2873 L 33.4546 33.4183 L 28.5673 33.3964 C 25.8764 33.3891 22.9382 33.3819 22.0364 33.3892 C 21.1345 33.3892 20.3491 33.3964 20.2909 33.3964 C 20.2327 33.3891 18.6327 33.3892 16.7491 33.3892 L 13.3091 33.3818 L 13.3091 29.3819 L 13.3091 25.3746 L 13.5491 25.3818 C 13.6727 25.3818 13.9492 25.3818 14.1601 25.3746 C 14.371 25.3746 14.5746 25.3891 14.6109 25.4109 C 14.6473 25.44 14.6982 25.4255 14.7273 25.3819 C 14.7564 25.3382 14.8074 25.3237 14.8437 25.3528 C 14.9092 25.3891 17.5564 25.4037 18.1091 25.36 C 18.2473 25.3527 18.4364 25.3673 18.5237 25.3964 C 18.611 25.4255 18.7055 25.4182 18.7273 25.3746 C 18.7564 25.3382 18.8073 25.3236 18.8436 25.3527 C 18.8873 25.3745 19.091 25.3963 19.2946 25.3891 C 19.5055 25.3818 19.7455 25.3819 19.8401 25.3819 C 20.1746 25.3819 21.4255 25.1637 21.9273 25.0183 C 22.4364 24.8655 22.56 24.8364 22.7637 24.7855 C 22.8219 24.7782 22.8873 24.7491 22.9091 24.7273 C 22.9309 24.7055 23.2073 24.56 23.5201 24.4073 C 24.1382 24.1164 24.7782 23.7019 25.1127 23.3891 C 25.2218 23.2873 25.3382 23.2001 25.3673 23.1928 C 25.4545 23.1855 26.2037 22.2619 26.5018 21.7964 C 26.8146 21.3164 27.3382 20.0655 27.3455 19.811 C 27.3455 19.731 27.3673 19.6364 27.3964 19.6073 C 27.4255 19.5782 27.4546 19.4327 27.4618 19.28 C 27.4618 19.1273 27.491 18.9601 27.5273 18.9092 C 27.6437 18.7201 27.5928 16.371 27.4546 15.7455 C 27.3891 15.4255 27.3237 15.1127 27.3092 15.0545 C 27.2946 14.96 27.2073 14.7127 27.0764 14.4 C 27.0546 14.3418 27.0255 14.2546 27.0255 14.2182 C 27.0036 14.0582 26.5382 13.2437 26.2255 12.8292 C 25.2219 11.4837 23.3019 10.2764 21.6364 9.92003 C 20.3346 9.64366 20.3564 9.65093 15.4473 9.62184 L 10.6327 9.59275 L 10.6037 9.81093 C 10.5818 9.93457 10.5964 10.0364 10.6255 10.0364 C 10.6546 10.0364 10.6546 10.1309 10.6183 10.2545 C 10.5819 10.3782 10.5819 10.4727 10.6183 10.4727 C 10.6547 10.4727 10.6547 10.5673 10.6183 10.6909 C 10.5819 10.8145 10.5819 10.9091 10.6183 10.9091 C 10.6547 10.9091 10.6547 11.0037 10.6183 11.12 C 10.5892 11.2291 10.5892 11.3673 10.6183 11.4255 C 10.6547 11.4764 10.6547 11.5709 10.6183 11.6364 C 10.5819 11.7019 10.5819 11.7964 10.6183 11.8546 C 10.6547 11.9128 10.6547 12.0073 10.6183 12.0728 C 10.5819 12.1382 10.5819 12.2328 10.6183 12.2909 C 10.6547 12.3491 10.6547 12.4436 10.6183 12.5164 C 10.5819 12.5818 10.5674 12.6546 10.5965 12.6764 C 10.6474 12.7346 10.6546 13.4473 10.5965 13.4982 C 10.5746 13.52 10.5892 13.6364 10.6183 13.7528 C 10.6547 13.8692 10.6547 13.9782 10.6183 14.0001 C 10.5892 14.0219 10.5892 14.1455 10.6183 14.2837 C 10.6474 14.4218 10.6474 14.5745 10.6183 14.6182 C 10.5892 14.6691 10.5892 14.8 10.6183 14.9164 C 10.6547 15.0255 10.6546 15.1345 10.6328 15.1636 C 10.5746 15.2145 10.5965 15.9055 10.6546 16 C 10.6765 16.0437 10.6692 16.0728 10.6256 16.0728 C 10.5819 16.0728 10.5819 16.1528 10.6184 16.291 C 10.6547 16.4146 10.6547 16.5092 10.6184 16.5092 C 10.582 16.5092 10.582 16.6037 10.6184 16.7273 C 10.6547 16.851 10.6547 16.9455 10.6184 16.9455 C 10.582 16.9455 10.582 17.0401 10.6184 17.1637 C 10.6547 17.2873 10.6547 17.3819 10.6184 17.3819 C 10.582 17.3819 10.582 17.4764 10.6184 17.6001 C 10.6547 17.7237 10.6547 17.8182 10.6184 17.8182 C 10.582 17.8182 10.582 17.9128 10.6184 18.0364 C 10.6547 18.1601 10.6547 18.2546 10.6184 18.2546 C 10.582 18.2546 10.582 18.3492 10.6184 18.4728 C 10.6547 18.5964 10.6547 18.691 10.6184 18.691 C 10.582 18.691 10.582 18.7855 10.6184 18.9092 C 10.6547 19.0328 10.6547 19.1273 10.6184 19.1273 C 10.582 19.1273 10.582 19.2219 10.6184 19.3455 C 10.6547 19.4692 10.6547 19.5637 10.6184 19.5637 C 10.582 19.5637 10.5675 19.6073 10.5893 19.6654 C 10.6547 19.84 10.6619 20.24 10.6038 20.4146 C 10.531 20.64 10.6983 20.7419 11.142 20.7346 C 12.0438 20.7128 12.2184 20.72 12.2838 20.7563 C 12.3202 20.7854 12.3711 20.771 12.3929 20.7346 C 12.422 20.6983 12.5238 20.6909 12.6256 20.72 C 12.7347 20.7491 12.931 20.7564 13.0619 20.7419 L 13.3092 20.7128 L 13.2947 16.3855 L 13.2729 12.0582 L 16.6547 12.0946 C 19.9492 12.131 20.5965 12.1745 20.9311 12.3854 C 20.9747 12.4218 21.0183 12.4291 21.0183 12.4073 C 21.0183 12.3346 21.8474 12.6619 22.2474 12.8873 C 23.5492 13.6146 24.2984 14.5819 24.662 16 C 24.8656 16.7782 24.8583 18.2909 24.6546 19.0837 C 24.4582 19.8618 24.0583 20.6546 23.6292 21.1055 C 23.4328 21.3164 23.2729 21.5127 23.2729 21.5418 C 23.2729 21.5709 23.2292 21.6 23.1783 21.6 C 23.1273 21.6 23.0182 21.6582 22.9382 21.7309 C 22.8 21.8473 22.7055 21.9055 22.2255 22.1745 C 21.8764 22.3709 21.1855 22.6182 20.5091 22.7855 C 19.9055 22.931 19.7165 22.9382 11.2219 22.96 L 2.54558 22.9891 L 2.54558 12.7346 L 2.54558 2.47276 L 14.6547 2.47276 L 26.7638 2.47276 L 26.7638 1.23643 L 26.7638 0 L 13.3819 0 Z M 29.3819 0 L 29.3819 1.23643 L 29.3819 2.47276 L 31.4182 2.47276 L 33.4546 2.47276 L 33.4546 4.50916 L 33.4546 6.54545 L 34.7273 6.54545 L 36 6.54545 L 36 3.27273 L 36 0 L 32.6909 0 Z" />
  </svg>
  </div>
  </a>
  </div>
  <br>
  <a href="mailto:mholub.ethz=gmail+com"><i class="fa fa-envelope-square"></i></a>
  <a href="https://orcid.org/0000-0002-8365-0927" target="_blank"><i class="ai ai-orcid"></i></a>
  <a href="https://github.com/martinholub" target="_blank"><i class="fa-brands fa-square-github"></i></a>
  <a href="/feed.xml" target="_blank"><i class="fa fa-rss-square"></i></a>
</span>


<div class="col three caption">
	&#169; Martin Holub, 2025
</div>
-->
  <script id="dsq-count-scr" src="//martinholub.disqus.com/count.js" async></script>
  <script src="/css/lightbox.js"></script>

  </body>
    <span class="contacticon center">
  <a href="https://www.instagram.com/scimartin/" target="_blank"><i class="fa-brands fa-square-instagram"></i></a>
  <a href="https://www.linkedin.com/in/scimartin" target="_blank"><i class="fa-brands fa-linkedin"></i></a>
  <a href="https://bsky.app/profile/scimartin.bsky.social" target="_blank"><i class="fa-brands fa-square-bluesky"></i></a>
  <div class="iconsuperwrapper">
  <a href="https://paragraph.xyz/@scimartin" target="_blank">
  <div class="iconwrapper">
  <svg
   class="icon"
   version="1.0"
   width="36"
   height="36"
   viewBox="0 0 36 36"
   preserveAspectRatio="xMidYMid meet"
   id="svg10"
   sodipodi:docname="paragraph.svg"
   inkscape:version="1.1.1 (3bf5ae0d25, 2021-09-20)"
   xmlns:inkscape="http://www.inkscape.org/namespaces/inkscape"
   xmlns:sodipodi="http://sodipodi.sourceforge.net/DTD/sodipodi-0.dtd"
   xmlns="http://www.w3.org/2000/svg"
   xmlns:svg="http://www.w3.org/2000/svg">
  <path
     id="path4"
     d="M 0 0 L 0 12.7273 L 0 25.4546 L 3.73818 25.4546 C 6.04363 25.4546 7.49818 25.4255 7.52727 25.3819 C 7.54909 25.3455 7.61454 25.331 7.66545 25.3528 C 7.82545 25.411 9.96371 25.4254 9.96371 25.3673 C 9.96371 25.3382 10.0073 25.331 10.0582 25.3528 C 10.1164 25.3746 10.2546 25.3964 10.371 25.4037 C 10.5383 25.4182 10.5819 25.4545 10.5746 25.5854 C 10.5746 25.6727 10.5964 25.7455 10.6255 25.7455 C 10.6546 25.7455 10.6546 25.84 10.6183 25.9564 C 10.5892 26.0655 10.5892 26.2036 10.6183 26.2618 C 10.6547 26.3127 10.6547 26.4073 10.6183 26.4728 C 10.5819 26.5382 10.5819 26.6327 10.6109 26.6764 C 10.64 26.7273 10.6473 26.9309 10.6183 27.1273 C 10.5892 27.3237 10.5964 27.5274 10.6255 27.5783 C 10.6546 27.6219 10.6546 27.7164 10.6183 27.7819 C 10.5819 27.8473 10.5819 27.9419 10.6183 28 C 10.6547 28.0582 10.6547 28.1528 10.6183 28.2182 C 10.5819 28.2837 10.5819 28.3782 10.6183 28.4364 C 10.6474 28.4873 10.6474 28.611 10.6183 28.6983 C 10.5747 28.8001 10.5819 28.8873 10.6183 28.9091 C 10.6547 28.9309 10.6547 29.0401 10.6183 29.1637 C 10.5819 29.2873 10.5819 29.3819 10.6183 29.3819 C 10.6547 29.3819 10.6547 29.4764 10.6183 29.6001 C 10.5819 29.7237 10.5819 29.8183 10.6183 29.8183 C 10.6547 29.8183 10.6547 29.9128 10.6183 30.0364 C 10.5819 30.1528 10.5746 30.2546 10.6037 30.2546 C 10.6328 30.2546 10.6546 30.3709 10.6546 30.5091 C 10.6546 30.6473 10.6328 30.7636 10.6037 30.7636 C 10.5746 30.7636 10.5819 30.8582 10.6183 30.9818 C 10.6547 31.0982 10.6547 31.2 10.6183 31.2 C 10.5892 31.2 10.5819 31.2874 10.6109 31.3965 C 10.64 31.5128 10.6401 31.7164 10.6183 31.8691 C 10.5892 32.0146 10.5892 32.1746 10.6255 32.2255 C 10.6546 32.2764 10.6546 32.371 10.6183 32.4364 C 10.5819 32.5019 10.5819 32.5964 10.6183 32.6546 C 10.6547 32.7128 10.6547 32.8073 10.6183 32.8728 C 10.5819 32.9383 10.5819 33.0328 10.6183 33.091 C 10.6474 33.1419 10.6474 33.2655 10.6183 33.3527 C 10.5747 33.4546 10.5819 33.5419 10.6183 33.5637 C 10.6547 33.5855 10.6547 33.6945 10.6183 33.8182 C 10.5819 33.9418 10.5819 34.0364 10.6183 34.0364 C 10.6547 34.0364 10.6547 34.1309 10.6183 34.2545 C 10.5819 34.3782 10.5819 34.4727 10.6183 34.4727 C 10.6547 34.4727 10.6547 34.5673 10.6183 34.6909 C 10.5819 34.8073 10.5746 34.9091 10.6037 34.9091 C 10.6619 34.9091 10.6546 35.4037 10.5965 35.4619 C 10.5747 35.4837 10.582 35.5782 10.6183 35.6727 C 10.6547 35.7673 10.6619 35.8618 10.6401 35.8837 C 10.611 35.9055 16.3128 35.9273 23.2946 35.9273 L 36 35.9273 L 36 22.5455 L 36 9.16364 L 34.7273 9.16364 L 33.4546 9.16364 L 33.4546 21.2873 L 33.4546 33.4183 L 28.5673 33.3964 C 25.8764 33.3891 22.9382 33.3819 22.0364 33.3892 C 21.1345 33.3892 20.3491 33.3964 20.2909 33.3964 C 20.2327 33.3891 18.6327 33.3892 16.7491 33.3892 L 13.3091 33.3818 L 13.3091 29.3819 L 13.3091 25.3746 L 13.5491 25.3818 C 13.6727 25.3818 13.9492 25.3818 14.1601 25.3746 C 14.371 25.3746 14.5746 25.3891 14.6109 25.4109 C 14.6473 25.44 14.6982 25.4255 14.7273 25.3819 C 14.7564 25.3382 14.8074 25.3237 14.8437 25.3528 C 14.9092 25.3891 17.5564 25.4037 18.1091 25.36 C 18.2473 25.3527 18.4364 25.3673 18.5237 25.3964 C 18.611 25.4255 18.7055 25.4182 18.7273 25.3746 C 18.7564 25.3382 18.8073 25.3236 18.8436 25.3527 C 18.8873 25.3745 19.091 25.3963 19.2946 25.3891 C 19.5055 25.3818 19.7455 25.3819 19.8401 25.3819 C 20.1746 25.3819 21.4255 25.1637 21.9273 25.0183 C 22.4364 24.8655 22.56 24.8364 22.7637 24.7855 C 22.8219 24.7782 22.8873 24.7491 22.9091 24.7273 C 22.9309 24.7055 23.2073 24.56 23.5201 24.4073 C 24.1382 24.1164 24.7782 23.7019 25.1127 23.3891 C 25.2218 23.2873 25.3382 23.2001 25.3673 23.1928 C 25.4545 23.1855 26.2037 22.2619 26.5018 21.7964 C 26.8146 21.3164 27.3382 20.0655 27.3455 19.811 C 27.3455 19.731 27.3673 19.6364 27.3964 19.6073 C 27.4255 19.5782 27.4546 19.4327 27.4618 19.28 C 27.4618 19.1273 27.491 18.9601 27.5273 18.9092 C 27.6437 18.7201 27.5928 16.371 27.4546 15.7455 C 27.3891 15.4255 27.3237 15.1127 27.3092 15.0545 C 27.2946 14.96 27.2073 14.7127 27.0764 14.4 C 27.0546 14.3418 27.0255 14.2546 27.0255 14.2182 C 27.0036 14.0582 26.5382 13.2437 26.2255 12.8292 C 25.2219 11.4837 23.3019 10.2764 21.6364 9.92003 C 20.3346 9.64366 20.3564 9.65093 15.4473 9.62184 L 10.6327 9.59275 L 10.6037 9.81093 C 10.5818 9.93457 10.5964 10.0364 10.6255 10.0364 C 10.6546 10.0364 10.6546 10.1309 10.6183 10.2545 C 10.5819 10.3782 10.5819 10.4727 10.6183 10.4727 C 10.6547 10.4727 10.6547 10.5673 10.6183 10.6909 C 10.5819 10.8145 10.5819 10.9091 10.6183 10.9091 C 10.6547 10.9091 10.6547 11.0037 10.6183 11.12 C 10.5892 11.2291 10.5892 11.3673 10.6183 11.4255 C 10.6547 11.4764 10.6547 11.5709 10.6183 11.6364 C 10.5819 11.7019 10.5819 11.7964 10.6183 11.8546 C 10.6547 11.9128 10.6547 12.0073 10.6183 12.0728 C 10.5819 12.1382 10.5819 12.2328 10.6183 12.2909 C 10.6547 12.3491 10.6547 12.4436 10.6183 12.5164 C 10.5819 12.5818 10.5674 12.6546 10.5965 12.6764 C 10.6474 12.7346 10.6546 13.4473 10.5965 13.4982 C 10.5746 13.52 10.5892 13.6364 10.6183 13.7528 C 10.6547 13.8692 10.6547 13.9782 10.6183 14.0001 C 10.5892 14.0219 10.5892 14.1455 10.6183 14.2837 C 10.6474 14.4218 10.6474 14.5745 10.6183 14.6182 C 10.5892 14.6691 10.5892 14.8 10.6183 14.9164 C 10.6547 15.0255 10.6546 15.1345 10.6328 15.1636 C 10.5746 15.2145 10.5965 15.9055 10.6546 16 C 10.6765 16.0437 10.6692 16.0728 10.6256 16.0728 C 10.5819 16.0728 10.5819 16.1528 10.6184 16.291 C 10.6547 16.4146 10.6547 16.5092 10.6184 16.5092 C 10.582 16.5092 10.582 16.6037 10.6184 16.7273 C 10.6547 16.851 10.6547 16.9455 10.6184 16.9455 C 10.582 16.9455 10.582 17.0401 10.6184 17.1637 C 10.6547 17.2873 10.6547 17.3819 10.6184 17.3819 C 10.582 17.3819 10.582 17.4764 10.6184 17.6001 C 10.6547 17.7237 10.6547 17.8182 10.6184 17.8182 C 10.582 17.8182 10.582 17.9128 10.6184 18.0364 C 10.6547 18.1601 10.6547 18.2546 10.6184 18.2546 C 10.582 18.2546 10.582 18.3492 10.6184 18.4728 C 10.6547 18.5964 10.6547 18.691 10.6184 18.691 C 10.582 18.691 10.582 18.7855 10.6184 18.9092 C 10.6547 19.0328 10.6547 19.1273 10.6184 19.1273 C 10.582 19.1273 10.582 19.2219 10.6184 19.3455 C 10.6547 19.4692 10.6547 19.5637 10.6184 19.5637 C 10.582 19.5637 10.5675 19.6073 10.5893 19.6654 C 10.6547 19.84 10.6619 20.24 10.6038 20.4146 C 10.531 20.64 10.6983 20.7419 11.142 20.7346 C 12.0438 20.7128 12.2184 20.72 12.2838 20.7563 C 12.3202 20.7854 12.3711 20.771 12.3929 20.7346 C 12.422 20.6983 12.5238 20.6909 12.6256 20.72 C 12.7347 20.7491 12.931 20.7564 13.0619 20.7419 L 13.3092 20.7128 L 13.2947 16.3855 L 13.2729 12.0582 L 16.6547 12.0946 C 19.9492 12.131 20.5965 12.1745 20.9311 12.3854 C 20.9747 12.4218 21.0183 12.4291 21.0183 12.4073 C 21.0183 12.3346 21.8474 12.6619 22.2474 12.8873 C 23.5492 13.6146 24.2984 14.5819 24.662 16 C 24.8656 16.7782 24.8583 18.2909 24.6546 19.0837 C 24.4582 19.8618 24.0583 20.6546 23.6292 21.1055 C 23.4328 21.3164 23.2729 21.5127 23.2729 21.5418 C 23.2729 21.5709 23.2292 21.6 23.1783 21.6 C 23.1273 21.6 23.0182 21.6582 22.9382 21.7309 C 22.8 21.8473 22.7055 21.9055 22.2255 22.1745 C 21.8764 22.3709 21.1855 22.6182 20.5091 22.7855 C 19.9055 22.931 19.7165 22.9382 11.2219 22.96 L 2.54558 22.9891 L 2.54558 12.7346 L 2.54558 2.47276 L 14.6547 2.47276 L 26.7638 2.47276 L 26.7638 1.23643 L 26.7638 0 L 13.3819 0 Z M 29.3819 0 L 29.3819 1.23643 L 29.3819 2.47276 L 31.4182 2.47276 L 33.4546 2.47276 L 33.4546 4.50916 L 33.4546 6.54545 L 34.7273 6.54545 L 36 6.54545 L 36 3.27273 L 36 0 L 32.6909 0 Z" />
  </svg>
  </div>
  </a>
  </div>
  <br>
  <a href="mailto:mholub.ethz=gmail+com"><i class="fa fa-envelope-square"></i></a>
  <a href="https://orcid.org/0000-0002-8365-0927" target="_blank"><i class="ai ai-orcid"></i></a>
  <a href="https://github.com/martinholub" target="_blank"><i class="fa-brands fa-square-github"></i></a>
  <a href="/feed.xml" target="_blank"><i class="fa fa-rss-square"></i></a>
</span>


<div class="col three caption">
	&#169; Martin Holub, 2025
</div>

</html>
